Also, combining XHP with PC chemotherapeutic agents and testing its ability to inhibit chemotherapeutic drug resistance by suppressing CYP3A4 expression is an avenue for future research that could provide insights into the potential clinical use of XHP as an adjunct therapy for the treatment of PC. Here, CYP3A4 is linked to pachyonychia congenita.